Why natural killer cells in triple negative breast cancer?

doi:10.5306/wjco.v11.i7.464

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 11, Issue 7

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (8865)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-4) series, Tables (1-1) series.

Item

Count

PDF

569

WORD

180

HTML

5311

Figures (1-4)

496

Tables (1-1)

232

Sum=6788

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

342

Download

534

Sum=876

Publishing Process of This Article

Item

Count

Browse

559

Download

642

Sum=1201

Jul 24, 2020 (publication date) through Jul 23, 2024

Times Cited of This Article

Times Cited (34)

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Clin Oncol. Jul 24, 2020; 11(7): 464-476
Published online Jul 24, 2020. doi: 10.5306/wjco.v11.i7.464

Full Size Figure Download Figure

Figure 4 Different modes of natural killer cell activation. Natural killer cell differential modes of activation when encountered with A: Healthy cells; B: Diseased cells with natural killer Ig-like receptors mismatch; C: Antibody-coated diseased cells; D: Diseased cells expressing natural killer lectin-like group 2, member D. NKG2D: Natural killer lectin-like group 2, member D; NKG2DL: Ligands of natural killer lectin-like group 2, member D; MHC: Major histocompatibility complex; KIR: Killer Ig-like receptor.

Citation: Abdel-Latif M, Youness RA. Why natural killer cells in triple negative breast cancer? World J Clin Oncol 2020; 11(7): 464-476
URL: https://www.wjgnet.com/2218-4333/full/v11/i7/464.htm
DOI: https://dx.doi.org/10.5306/wjco.v11.i7.464